Canine Myasthenia Gravis: Diagnosis and Management

Bottom line

Acquired myasthenia gravis (MG) is an autoimmune neuromuscular-junction disorder that can be focal, generalized, or acutely fulminant. [1] A negative acetylcholine-receptor (AChR) antibody assay does not end the investigation when the phenotype remains compelling. Esophageal weakness and thymoma were associated with poorer outcomes in a recent referral case series. [2]

Describe the phenotype before assigning the diagnosis

Document fatigability, recovery with rest, limb function, swallowing, regurgitation, voice change, respiratory status, and the neurological examination. Separate a suspected junctional disorder from peripheral neuropathy, myopathy, spinal disease, and systemic weakness.

The classification review separates autoimmune MG from genetic congenital myasthenic syndromes. Pharmacological improvement can support MG, but other neuromuscular diseases may respond subjectively, and a negative challenge can occur in MG. [1] Neither young age nor a treatment response should replace a reasoned diagnostic assessment.

Use serology with a plan for discordance

AChR antibody testing is central to confirmation. Early disease or prior immunosuppression can produce negative results; electrophysiology and pharmacological testing provide complementary evidence. [1]

The 2025 retrospective series included seronegative dogs on clinical and ancillary-test criteria. The authors acknowledge that another neuromuscular disorder could occasionally mimic MG and that definitive tests for these patients remain needed. [2] Do not turn a negative assay plus nonspecific weakness into a confirmed seronegative diagnosis.

Record the assay, medication history, timing, and supporting localization. Discuss repeat testing and specialist electrodiagnostics when results disagree with the clinical picture rather than escalating medication to prove a label.

Assess the esophagus and lungs independently of limb strength

Improved walking is not evidence that swallowing or esophageal function is safe. In the recent case series, esophageal weakness was associated with reduced survival and a lower likelihood of remission; retrospective selection and diagnostic limitations constrain individual prognosis. [2]

The esophageal regurgitation workup helps characterize passive return and competing structural or motility disease. The aspiration pneumonia reference addresses the separate question of lung injury, sampling, and antimicrobial decisions.

Assess the need for admission or referral when respiratory effort, airway protection, intake, or hydration cannot be managed safely. Provide the receiving team with the neurological examination, original thoracic images, nutritional history, and treatment record.

Separate symptomatic treatment from immune treatment

Acetylcholinesterase inhibitors such as pyridostigmine are used for symptomatic treatment. The classification review suggests adding immunosuppression selectively when symptomatic therapy is inadequate, while recognizing aspiration-pneumonia risk and potentially serious cholinergic adverse effects. [1]

Specify what each proposed treatment is intended to change. New weakness, secretions, gastrointestinal signs, or respiratory deterioration warrants reassessment of both disease and treatment tolerance; do not assume that every deterioration requires more anticholinesterase medication.

A retrospective comparison found no significant difference in remission, time to remission, or survival between pyridostigmine alone and pyridostigmine plus mycophenolate mofetil. Its results did not support routine mycophenolate use. [3] A small nonrandomized comparison cannot exclude benefit in every selected patient, but it does not justify automatic combination therapy.

Drug use may be extra-label depending on product and jurisdiction. Reconcile formulation, indication, infection status, and monitoring with the treating neurologist before prescribing.

Investigate thymoma and define follow-up endpoints

Thoracic imaging is important for evaluating a cranial mediastinal mass, including thymoma. [1] Record whether the mass question has been answered rather than treating all MG cases as one prognostic group.

Follow limb function, regurgitation, respiratory events, nutritional adequacy, medication tolerance, and diagnostic certainty separately. Agree on how clinical improvement, continued treatment dependence, and possible remission will be evaluated. Avoid promising a universal spontaneous-remission rate from a population that differs from the patient in front of you.

Frequently Asked Questions

Does negative AChR serology exclude acquired MG?

No. Seronegative cases occur, and early disease or immunosuppression can complicate interpretation. [1]

Is improvement after an anticholinesterase challenge diagnostic by itself?

No. Subjective improvement can occur in other neuromuscular disorders, and some MG cases have negative challenges. [1]

Does the recent seronegative case series eliminate diagnostic uncertainty?

No. Its authors acknowledge possible mimics and the need for better definitive tests. [2]

Does better limb strength prove the esophageal problem has resolved?

No. Esophageal weakness was an important adverse outcome association in the referral cohort. [2] Assess swallowing and regurgitation independently.

Should mycophenolate routinely accompany pyridostigmine?

The retrospective comparison did not support routine use; remission and survival outcomes did not significantly differ between groups. [3]

Why assess for a cranial mediastinal mass?

Thymoma-associated MG is a distinct subgroup, and thoracic imaging is part of its evaluation. [1]

Can the referral cohort supply a universal prognosis?

No. Retrospective selection, subgroup differences, and diagnostic uncertainty limit application to an individual dog. [2]